DGAP-News: Novavax Appoints John J. Trizzino as Senior Vice

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 10, 2014 at 8:45 AM

DGAP-News: Novavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations

DGAP-News: Novavax, Inc. / Novavax Appoints John J. Trizzino as Senior Vice President, Commercial Operations 10.03.2014 / 13:30 --------------------------------------------------------------------- GAITHERSBURG, Md., 2014-03-10 13:30 CET (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the appointment of John J. Trizzino to the position of Senior Vice President, Commercial Operations, effective March 10, 2014. Mr. Trizzino will be responsible for developing and implementing the commercialization strategy in support of the company's product candidates, including its RSV F, quadrivalent seasonal and pandemic influenza vaccine candidates. Mr. Trizzino previously served as Novavax' Senior Vice President of International and Government Alliances beginning in 2009 and its Senior Vice President of Business Development from 2010 to 2011. In these roles, Mr. Trizzino played a key role in negotiating the company's $179 million contract with HHS BARDA. Mr. Trizzino brings the depth and breadth of vaccine industry knowledge, along with extensive experience with the global influenza and RSV markets, required for this position. Most recently he was the CEO of Immunovaccine, and prior to his time at Novavax, served as Vice President of the Vaccine Franchise at MedImmune LLC, Senior Vice President of Business Development at ID Biomedical and Vice President of Business Development at Henry Schein, Inc., all the while having commercial responsibility within the pediatric and adult infectious disease vaccine market. 'With our success in product development in the clinic, and our expectations around future development plans, we recognize the need to maximize the value of our vaccine candidates through a fully developed commercialization strategy. John's knowledge of the vaccine industry, with specific experience in vaccine commercialization, distribution and reimbursement, provide us with the insight needed to develop that commercialization strategy,' said Stan Erck, President and CEO of Novavax. 'We are very excited to have John return to the team and look forward to his contributions to our success.' 'Novavax is at an important milestone in the development of its RSV, seasonal influenza and pandemic influenza vaccines. As these vaccine candidates move into the later stages of clinical development it is the right time to develop a commercialization strategy to ensure a successful path to market. Novavax' RSV vaccine has the opportunity to be the first vaccine to address the significant burden of this disease in both the very old and the very young. The cost of treating RSV illness, hospitalization and preventing loss of life is a multibillion dollar global market opportunity. I am looking forward to working with the Novavax team again in pursuit of these and the other vaccine candidates in its pipeline.' About Novavax Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant protein nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Additional information about Novavax is available on the company's website, novavax.com. Forward-Looking Statements Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading 'Risk Factors' in the Novavax Annual Report on Form 10-K for the year ended December 31, 2013, and filed with the Securities and Exchange Commission (SEC). Investors are cautioned not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read company filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and the company undertakes no obligation to update or revise any of the statements. The company's business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. CONTACT: Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000 News Source: NASDAQ OMX End of Corporate News --------------------------------------------------------------------- 10.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Novavax, Inc. United States ISIN: US6700021040 End of News DGAP News-Service --------------------------------------------------------------------- 256686 10.03.2014

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lupin Grabs FDA Nod: What Investors Should Know

Lupin's Big Break Let's cut right to the chase: Lupin's latest FDA approval is no small potatoes. It's like getting a golden ticket in the pharma world, especially when you've been in the trenches as long as they have. As the first-to-file for their Amifampridine Tablets, 10 mg, this Indian giant is snagging that sweet 180-day exclusivity window. And in the cutthroat...

ADC Therapeutics Preps Financial Results Release

ADC Therapeutics: Eyes on the Financial Prize So here we are, folks—ADC Therapeutics is blitzing the stage and gearing up to spill the beans on their third-quarter saga come November 9, 2026. Who needs a crystal ball when you've got a press release to dissect every number and nuance? Anticipating the Numbers: What's at Stake? ADC Therapeutics has been riding the wave of...

Northwood's $375M Boost: Satellite Network Expansion

Northwood's Bold Leap into Space Connectivity Here's a nugget of info that could jolt your morning coffee: Northwood Space Corp—yeah, the folks linking satellites to Earth—just pulled in a whopping $375 million in Series C funding. This ain't your average capital injection; it's a full-throttle push to broaden their ground network reach and revamp space...

JobPlanner Boosts Tools to Shield Margins in Construction

Real-Time Solutions for Real-World Challenges JobPlanner is stepping up its game with some beefed-up financial management tools, and I gotta admit, it's like a lifeline in the raging sea of construction costs. We're talking about a souped-up Real-Time Job Costing Suite tailored for general and specialty contractors who are tired of watching their profits evaporate into...

Atlas Power Expands with Boyland Electric Acquisition

The Strategy Behind Atlas Power's Expansion Atlas Power Partners, no stranger to sizzling ambitions, has galvanized its portfolio by roping in Boyland Electric. This latest maneuver unfolds as Atlas hustles to become the go-to network for residential generator services. It’s a clear bet on 'quality over flair'—an ethos echoed by their CEO, David Fischer, who champions...

First FedRAMP® 20x Class C Certification Earned

Shifting Landscapes in Cybersecurity Certifications Change is the only constant in tech, and 360 Advanced sure knows how to ride that wave by leaping into the murky waters of FedRAMP's newest class. They’ve stamped their name on this historic FedRAMP® 20x Class C Certification by playing the role of the independent assessor for Perplexity's cloud service—a first...

Vanity Fair Lingerie Reveals New Smoothing Bra

A Bra Revolution or Just Another Launch? I'll admit it, lingerie isn't the usual breakfast discussion for me, but Vanity Fair Lingerie's move with their new Flawlessly Smooth™ Bra piqued my interest. Announced in Bowling Green, Kentucky, on November 2, 2026, and set against the lavish backdrop of an upcoming New York City event cohosted by Cosmopolitan, it's less about...

Endeavor & GoPath's Game-Changing Cancer Test Launch

Breaking Ground in Prostate Cancer Testing Just when you thought the medical field couldn't shake things up further, Endeavor Health and GoPath Diagnostics swoop in with a new genetic test for prostate cancer. This ain't just any run-of-the-mill test—it's the first of its kind to hit the clinical scene. The focus here is on sorting out which men with prostate cancer are...

Xylitol: A Game Changer in Kids' Oral Care Battle

Candy Challenges: Embracing Sweet Joys Responsibly Think you're done with Halloween? Nope. Welcome to the endless candy seasons when every festivity seems like an outlet for sugar overload—with parents caught between letting kids enjoy and guarding their teeth. Now, with Spry's recent push around xylitol, there's an option that might just mean an easier peace between...

Wet Noses Innovates Human-Grade Pet Food at PLMA 2026

Pet Food Revolution? Wet Noses Takes the PLMA Stage Okay, listen up, pet lovers and industry folks alike—seems like Wet Noses, that Washington-based veteran in the dog treat game, is shaking up the pet food world. After cruising through the pet aisle for almost three decades, they're making a splash at the PLMA 2026. Why should we care? Well, they’re pushing this...